Published in Res Commun Chem Pathol Pharmacol on October 01, 1986
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med (1994) 2.66
Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine (1992) 1.63
Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest (1992) 1.58
Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest (1994) 1.50
Clinical evaluation of an acellular allograft dermal matrix in full-thickness burns. J Burn Care Rehabil (1996) 1.48
Burn depth: a review. World J Surg (1993) 1.32
Is immediate decompression of high voltage electrical injuries to the upper extremity always necessary? J Trauma (1996) 1.21
Alcohol use and burn injury. J Burn Care Rehabil (1991) 1.15
Dietary requirements of patients with major burns. J Am Diet Assoc (1974) 1.09
Synthetic burn dressings: round table discussion. J Burn Care Rehabil (1987) 1.07
Intraocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. J Ocul Pharmacol (1994) 1.05
Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol (1999) 1.05
Simultaneous contralateral testicular metastasis from a renal clear cell carcinoma. Scand J Urol Nephrol (1999) 1.04
Burn patients, then and now. Burns (1999) 1.03
Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist. J Pharm Sci (1995) 0.93
Surveillance of burn wound infections: a proposal for definitions. J Burn Care Rehabil (1998) 0.91
Evaluation of eight methods for estimating creatinine clearance in men. Clin Pharm (1987) 0.91
Hormone levels in vegetarian and nonvegetarian teenage girls: potential implications for breast cancer risk. Cancer Res (1992) 0.90
Serum binding of tocainide and its enantiomers in human subjects. Res Commun Chem Pathol Pharmacol (1982) 0.90
Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defense. J Appl Physiol (1985) (1992) 0.89
Serial measurements increase the accuracy of laser Doppler assessment of burn wounds. J Burn Care Rehabil (2003) 0.89
Methylprednisolone achieves greater concentrations in the lung than prednisolone. A pharmacokinetic analysis. Am Rev Respir Dis (1991) 0.88
Diagnosis-related groupings (DRGs) and wound closure: roundtable discussion. J Burn Care Rehabil (1987) 0.88
Prognosis and treatment of burns. West J Med (1996) 0.86
Postburn serum drug binding and serum protein concentrations. J Clin Pharmacol (1986) 0.86
Reduced muscle protein breakdown in septic rats following treatment with interleukin-1 receptor antagonist. Int J Biochem (1994) 0.84
Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column. Radiology (1991) 0.84
Pharmacodynamics of midodrine, an antihypotensive agent. Clin Pharmacol Ther (1986) 0.83
Full-thickness burn to the hand from an automobile airbag. J Burn Care Rehabil (2000) 0.83
Nephrogenic adenoma in children. Case report and review of literature. Eur J Pediatr Surg (1997) 0.83
Safety and efficacy of emamectin benzoate to treat Anguillicoloides crassus (Kuwahara, Niimi & Itagaki) infections in American eels, Anguilla rostrata (Lesueur). J Fish Dis (2012) 0.81
Ureterosciatic hernia. Scand J Urol Nephrol (1996) 0.80
Pharmacokinetics of diltiazem in selected animal species and human beings. Am J Cardiol (1982) 0.80
Mechanics of venom expulsion in Crotalus, with special reference to the role of the fang sheath. Anat Rec (2001) 0.80
Chemolysis of struvite stones by acidification of artificial urine--an in vitro study. Scand J Urol Nephrol (2001) 0.79
Pharmacokinetics of insulin-like growth factor-1 in advanced chronic renal failure. Kidney Int (1996) 0.79
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of alfentanil. Anesthesiology (1999) 0.78
Results of a multicenter outpatient burn study on the safety and efficacy of Dimac-SSD, a new delivery system for silver sulfadiazine. J Trauma (1989) 0.78
Improved accuracy of burn wound assessment using laser Doppler. J Trauma (1996) 0.78
Value of prostate-specific antigen as a tumor marker. Eur Urol (1993) 0.78
Withdrawal from positive end-expiratory pressure. Surgery (1978) 0.78
Fluid and electrolyte therapy of burn shock. Heart Lung (1973) 0.78
Hydronephrosis after aorto bifemoral graft surgery: a marker for late graft complications. Scand J Urol Nephrol (1999) 0.77
Experience with skeletal immobilization after excision and grafting of severely burned hands. J Trauma (1985) 0.77
Dr. Paul Unna's boot and early ambulation after skin grafting the leg: a survey of burn centers and a report of 20 cases. Plast Reconstr Surg (1982) 0.77
Use of pain assessment tools: is there a preference? J Burn Care Rehabil (1998) 0.77
Effects of lipids on bioavailability of sulfisoxazole acetyl, dicumarol, and griseofulvin in rats. J Pharm Sci (1976) 0.77
Pharmacokinetics of insulin-like growth factor I in hypopituitarism: correlation with binding proteins. Am J Physiol (1999) 0.76
Effect of nasolacrimal occlusion on timolol concentrations in the aqueous humor of the human eye. J Pharm Sci (1992) 0.76
Adjunctive interventions for burn pain control: comparison of hypnosis and ativan: the 1993 Clinical Research Award. J Burn Care Rehabil (1994) 0.76
The effect of tumor necrosis factor alpha on a human renal cell carcinoma xenotransplanted into nude mice: comparison of intravenous and intraperitoneal injection. Oncology (1995) 0.76
A new type of artificial urinary calculi: in vitro study by spiral CT. Invest Radiol (2000) 0.76
N-acetyl-beta-D-glucosaminidase excretion in calcium oxalate stone patients and its relation to the risk of stone formation. Scand J Urol Nephrol (1996) 0.75
Use of hyperbaric oxygen. Clin Infect Dis (1993) 0.75
A readily obtainable analog of propranolol suitable for use as internal standard in chromatographic assays for propranolol. Res Commun Chem Pathol Pharmacol (1985) 0.75
Lidocaine pharmacokinetics in pregnant and nonpregnant sheep. J Pharm Sci (1980) 0.75
Who speaks for the little burn? Burns (1996) 0.75
Supportive therapy in burn care. Dealing with clinical questions. J Trauma (1979) 0.75
Advanced preparation for clinical specialists in burns. J Emerg Nurs (1975) 0.75
Sarcoptes scabei bovis--a potential danger. J Am Vet Med Assoc (1975) 0.75
Manifestation of metabolic risk factors after renal transplantation: III. Impact on cerebrocardiovascular complications. Transplant Proc (1995) 0.75
Anesthesia-assisted procedures in a burn intensive care unit procedure room: benefits and complications. J Burn Care Rehabil (1993) 0.75
Minor burns: guidelines for successful outpatient management. Postgrad Med (1981) 0.75
[Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma]. Urologe A (1993) 0.75
Manifestation of metabolic risk factors after renal transplantation: II. Impact of maintenance therapy. Transplant Proc (1995) 0.75
Saturable first-pass metabolism of sulfisoxazole N1-acetyl in rats. J Pharm Sci (1976) 0.75
Pulmonary microembolism: a cause of lung injury. J Surg Res (1987) 0.75
The role of autopsy on patients with burns. J Burn Care Rehabil (2000) 0.75
Mechanical debridement. Views from University of Washington Burn Center at Harborview, Seattle, Washington. J Burn Care Rehabil (1989) 0.75
Contact burns of the hand. Pediatrics (1987) 0.75
Nonlinear pharmacokinetics of ethanol elimination in long sleep and short sleep mice. Alcohol Clin Exp Res (1983) 0.75
Open heart surgery in a community hospital. IMJ Ill Med J (1985) 0.75
A pharmacokinetic model describing the removal of circulating radiolabeled antibody by extracorporeal immunoadsorption. J Pharmacokinet Biopharm (1991) 0.75
Chemolysis of artificial cystine stones (BON(N)-STONES) in vitro using a new dissolution device: first results. J Endourol (2000) 0.75
Treatment of a human renal cell carcinoma in nude mice with recombinant human tumor necrosis factor alpha and etoposide. J Urol (1993) 0.75
Pharmacokinetics of intravenous chlorpheniramine in children. J Pharm Sci (1981) 0.75
Results of donor kidney pairs after local versus HLA-dependent allocation. Transplant Proc (1997) 0.75
Serum binding of diltiazem in humans. J Clin Pharmacol (1982) 0.75
Imaging of non-small cell lung cancers with a monoclonal antibody, KC-4G3, which recognizes a human milk fat globule antigen. Cancer Res (1990) 0.75
[Surgical interventions of the adrenal gland. Diagnosis and results of treatment]. Urologe A (1994) 0.75
Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug. Xenobiotica (2008) 0.75
Blood flow and oxygen extraction in ischaemic and normal regions of the myocardium following acute coronary artery ligation. J Physiol (1973) 0.75
Surgical fixation of skin grafts. Comments from the University of Washington, Seattle, Washington. J Burn Care Rehabil (1989) 0.75
In-vivo stimulation of cell-proliferation of 2 human tumor xenograft lines by granulocyte-macrophage colony-stimulating factor (gm-csf). Oncol Rep (1994) 0.75
From the Nursing Forum editors: a tribute from Charlie's Angels. J Burn Care Rehabil (1999) 0.75
The burn surgeon and the need for critical care certification. J Burn Care Rehabil (1990) 0.75
Comparative study of 99mTc labeled hepatobiliary agents based on naphthalene and similar ring systems. Int J Nucl Med Biol (1982) 0.75
On the conversion of verapamil to carboxy verapamil. Res Commun Chem Pathol Pharmacol (1986) 0.75
Burn care protocols--infection control in burn unit. Review of infection control procedure at Jackson Memorial Hospital Burn Center, From Harborview Hospital, Seattle. J Burn Care Rehabil (1987) 0.75
Comparison of 99mTc-N-pyridoxyl-5-methyltryptophan and 99mTc-N-(3-bromo-2,4,6-trimethylacetanilide)-iminodiace tate as hepatobiliary radiopharmaceuticals in rats. J Pharm Sci (1984) 0.75
Ketamine kinetics: decerebrate vs. intact cats. Can J Physiol Pharmacol (1979) 0.75
Manifestation of metabolic risk factors after renal transplantation: I: Association with long-term allograft function. Transplant Proc (1995) 0.75
Recipe for postgraft antimicrobial wound cover. J Burn Care Rehabil (1995) 0.75
The fourth quinquennium: 1984 to 1988. J Burn Care Rehabil (1993) 0.75
Conscious sedation. Viewpoints from Shands Hospital at the University of Florida. J Burn Care Rehabil (1999) 0.75